Barry Canton Sells 37,650 Shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Stock

Ginkgo Bioworks Holdings, Inc. (NYSE:DNAGet Rating) major shareholder Barry Canton sold 37,650 shares of Ginkgo Bioworks stock in a transaction on Wednesday, January 4th. The shares were sold at an average price of $1.56, for a total transaction of $58,734.00. Following the transaction, the insider now owns 17,750,024 shares in the company, valued at approximately $27,690,037.44. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Major shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Barry Canton also recently made the following trade(s):

  • On Monday, December 19th, Barry Canton sold 206,448 shares of Ginkgo Bioworks stock. The shares were sold at an average price of $1.67, for a total transaction of $344,768.16.
  • On Thursday, December 15th, Barry Canton sold 103,547 shares of Ginkgo Bioworks stock. The shares were sold at an average price of $1.61, for a total transaction of $166,710.67.
  • On Tuesday, December 13th, Barry Canton sold 98,934 shares of Ginkgo Bioworks stock. The shares were sold at an average price of $1.89, for a total transaction of $186,985.26.
  • On Thursday, December 8th, Barry Canton sold 97,204 shares of Ginkgo Bioworks stock. The stock was sold at an average price of $1.79, for a total transaction of $173,995.16.
  • On Tuesday, December 6th, Barry Canton sold 103,392 shares of Ginkgo Bioworks stock. The stock was sold at an average price of $1.73, for a total transaction of $178,868.16.
  • On Tuesday, November 29th, Barry Canton sold 96,434 shares of Ginkgo Bioworks stock. The stock was sold at an average price of $1.90, for a total transaction of $183,224.60.
  • On Wednesday, November 23rd, Barry Canton sold 99,797 shares of Ginkgo Bioworks stock. The stock was sold at an average price of $1.99, for a total transaction of $198,596.03.
  • On Monday, November 21st, Barry Canton sold 103,764 shares of Ginkgo Bioworks stock. The stock was sold at an average price of $2.10, for a total transaction of $217,904.40.
  • On Wednesday, November 16th, Barry Canton sold 219,088 shares of Ginkgo Bioworks stock. The stock was sold at an average price of $2.42, for a total transaction of $530,192.96.
  • On Monday, November 14th, Barry Canton sold 208,632 shares of Ginkgo Bioworks stock. The stock was sold at an average price of $2.72, for a total transaction of $567,479.04.

Ginkgo Bioworks Trading Down 3.2 %

Shares of NYSE:DNA opened at $1.52 on Friday. The company has a quick ratio of 11.67, a current ratio of 11.71 and a debt-to-equity ratio of 0.04. Ginkgo Bioworks Holdings, Inc. has a fifty-two week low of $1.45 and a fifty-two week high of $7.37. The firm has a 50-day simple moving average of $2.00 and a 200 day simple moving average of $2.59.

Ginkgo Bioworks (NYSE:DNAGet Rating) last announced its quarterly earnings data on Monday, November 14th. The company reported ($0.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.15). Ginkgo Bioworks had a negative net margin of 668.49% and a negative return on equity of 85.90%. The business had revenue of $66.40 million for the quarter, compared to the consensus estimate of $54.28 million. On average, sell-side analysts predict that Ginkgo Bioworks Holdings, Inc. will post -1.41 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the stock. Berenberg Bank assumed coverage on shares of Ginkgo Bioworks in a research report on Monday, November 28th. They issued a “buy” rating and a $6.00 target price for the company. Raymond James dropped their target price on shares of Ginkgo Bioworks from $10.50 to $6.00 and set an “outperform” rating for the company in a research report on Tuesday, November 22nd. BTIG Research dropped their target price on shares of Ginkgo Bioworks to $4.00 in a research report on Thursday, November 17th. Finally, Morgan Stanley assumed coverage on shares of Ginkgo Bioworks in a research report on Tuesday, October 4th. They issued an “equal weight” rating and a $5.00 target price for the company. One analyst has rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $5.92.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Almanack Investment Partners LLC. boosted its stake in Ginkgo Bioworks by 22.3% during the 2nd quarter. Almanack Investment Partners LLC. now owns 17,850 shares of the company’s stock valued at $42,000 after purchasing an additional 3,250 shares during the period. 180 Wealth Advisors LLC boosted its stake in Ginkgo Bioworks by 14.2% during the 2nd quarter. 180 Wealth Advisors LLC now owns 30,094 shares of the company’s stock valued at $72,000 after purchasing an additional 3,733 shares during the period. Treasurer of the State of North Carolina boosted its stake in Ginkgo Bioworks by 1.3% during the 3rd quarter. Treasurer of the State of North Carolina now owns 351,677 shares of the company’s stock valued at $1,097,000 after purchasing an additional 4,540 shares during the period. Formidable Asset Management LLC boosted its stake in Ginkgo Bioworks by 32.1% during the 2nd quarter. Formidable Asset Management LLC now owns 20,332 shares of the company’s stock valued at $64,000 after purchasing an additional 4,946 shares during the period. Finally, Bradley Foster & Sargent Inc. CT boosted its stake in Ginkgo Bioworks by 7.3% during the 2nd quarter. Bradley Foster & Sargent Inc. CT now owns 74,390 shares of the company’s stock valued at $177,000 after purchasing an additional 5,035 shares during the period. 61.83% of the stock is owned by institutional investors and hedge funds.

Ginkgo Bioworks Company Profile

(Get Rating)

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals.

Featured Articles

Insider Buying and Selling by Quarter for Ginkgo Bioworks (NYSE:DNA)

Receive News & Ratings for Ginkgo Bioworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ginkgo Bioworks and related companies with MarketBeat.com's FREE daily email newsletter.